Altamira Announces Patent Office Decision to Grant for Intranasal Betahistine
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it has completed enrollment in its Phase 1b proof-of-concept trial of AM-201, the Company’s investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.
EMA recommends suspension of medicines due to unreliable studies from Micro Therapeutic Research Labs
Pharmascience Inc. recalls Betahistine due to Labelling error
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.